Collectively, these future investigations will clarify the therapeutic relevance of PAR-2 suppression by OC in chondrosarcoma and establish a framework for the clinical translation of OC-based multimodal therapies targeting tumor inflammation, stemness, metabolism, and the immunosuppressive microenvironment. Here, F2RL1 is linked to neoplasm.